Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03404076 | Unifying Advanced Treatment With Advanced Imaging(GISTm3) | completed | — | 93 | Heidelberg UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT01933958 | Regorafenib Post-marketing Surveillance in Japan | completed | — | 72 | BayerINDUSTRY | 1 | Apr 1, 2022 | clinicaltrials |
| Liver Transplantation for Unresectable GIST Liver Metastases(TRANSGIST) |
| unknown |
| N/A |
| 50 |
| Hospital Universitario Virgen de la ArrixacaOTHER |
| 1 |
| Mar 11, 2022 |
| clinicaltrials |
| NCT02924714 | SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST | suspended | N/A | 31 | Oslo University HospitalOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05197933 | Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach | unknown | N/A | 182 | RenJi HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05080621 | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | withdrawn | Phase 1 / Phase 2 | 0 | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | Jan 5, 2022 | clinicaltrials |
| NCT04751591 | Study On Safety Of Endoscopic Resection For 2-5cm Gastric Gastrointestinal Stromal Tumor | unknown | N/A | 260 | Shanghai Zhongshan HospitalOTHER | 0 | Nov 30, 2021 | clinicaltrials |
| NCT05132738 | Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy | unknown | N/A | 20 | RenJi HospitalOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT04933669 | Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors(ZJGIST-01) | recruiting | Phase 2 | 122 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT05001204 | 68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT02216578 | Ph II CABOGIST in GIST | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 15, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT02164240 | Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST(SURE) | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT03158103 | A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04761172 | NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours | unknown | Phase 2 / Phase 3 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01271712 | Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)(GRID) | completed | Phase 3 | 199 | BayerINDUSTRY | 17 | Jan 29, 2021 | clinicaltrials |
| NCT00135005 | Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) | completed | Phase 1 | 59 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT01694277 | Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib | completed | Phase 3 | 258 | AB ScienceINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT02185937 | Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy(ABILITY) | terminated | Phase 1 | 5 | Radboud University Medical CenterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT00028002 | Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 26, 2020 | clinicaltrials |
| NCT00510354 | Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate(Radix) | completed | Phase 4 | 28 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01068769 | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | completed | Phase 2 | 34 | Suzanne George, MDOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03880617 | Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy | completed | — | 297 | National Taiwan University HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT03862885 | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03426722 | L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors | completed | Phase 3 | 4 | Asan Medical CenterOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT04256226 | Clinical Outcome of Female Non-gastric Gastrointestinal Stromal Tumor | completed | — | 26 | Far Eastern Memorial HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04148092 | Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | approved for marketing | — | — | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | May 29, 2020 | clinicaltrials |
| NCT04143048 | A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules | unknown | — | 300 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT04343456 | Salvage Surgery for Patients With Metastatic GIST With Rego | completed | — | 41 | Chang Gung Memorial HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00718211 | A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore | completed | — | — | National University Hospital, SingaporeOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02015065 | Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02257541 | BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT04269941 | Prognostic Factors Affecting Survival of Gastric GIST | completed | — | 34 | Université de SousseOTHER | 0 | Feb 17, 2020 | clinicaltrials |
| NCT01440959 | Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 | completed | Phase 2 | 30 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01151852 | Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT | completed | Phase 3 | 81 | Asan Medical CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01178307 | Symptom Inventory for Gastrointestinal Stromal Tumors | unknown | — | 187 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02889328 | Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs | completed | Phase 2 | 25 | Asan Medical CenterOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT00278876 | Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation | completed | Phase 2 | 47 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT00976612 | Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK | completed | — | 17 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02607332 | Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | completed | Phase 2 | 25 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03440515 | Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor | completed | Phase 2 | 29 | Asan Medical CenterOTHER | 0 | Jan 7, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT02574663 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | completed | Phase 1 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02931929 | MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT | completed | Phase 1 / Phase 2 | 9 | Medical University InnsbruckOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02686944 | A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors(GIST) | completed | Phase 1 | 6 | MendusINDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT00568750 | Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors | completed | Phase 2 | 47 | Swiss Cancer InstituteOTHER | 4 | Jun 17, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2022source: clinicaltrials